Mutual of America Capital Management LLC Has $3.96 Million Stock Position in Halozyme Therapeutics, Inc. $HALO

Mutual of America Capital Management LLC lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 11.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 54,018 shares of the biopharmaceutical company’s stock after selling 7,261 shares during the period. Mutual of America Capital Management LLC’s holdings in Halozyme Therapeutics were worth $3,962,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Campbell Newman Asset Management Inc. raised its position in shares of Halozyme Therapeutics by 0.4% during the third quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after purchasing an additional 153 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares during the last quarter. Richardson Financial Services Inc. lifted its stake in shares of Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 198 shares in the last quarter. Brown Advisory Inc. grew its holdings in shares of Halozyme Therapeutics by 0.6% during the second quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 224 shares during the last quarter. Finally, Global Retirement Partners LLC grew its holdings in shares of Halozyme Therapeutics by 21.6% during the third quarter. Global Retirement Partners LLC now owns 1,413 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 251 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO stock opened at $73.34 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The firm has a market cap of $8.62 billion, a PE ratio of 15.44, a P/E/G ratio of 0.32 and a beta of 0.94. The business has a 50 day moving average of $68.90 and a 200-day moving average of $68.27. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The business had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The business’s revenue was up 22.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.27 earnings per share. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company raised guidance and posted strong preliminary 2025 metrics — Halozyme updated preliminary 2025 revenue to $1.385–$1.40B and raised 2026 revenue guidance to $1.71–$1.81B; it also lifted royalty, adjusted EBITDA and non‑GAAP EPS guidance, signaling stronger top‑line and cash‑flow outlooks. PR Newswire
• Positive Sentiment: Market reacted to the stronger preliminary results and raised outlook — coverage notes a near‑term share uptick after management lifted 2026 guidance and preliminary 2025 results beat expectations. This supports momentum and re‑rates HALO on growth expectations. Zacks
• Positive Sentiment: Acquisition of Surf Bio expands drug‑delivery capabilities — Halozyme bought Surf Bio (deal up to $400M) to add a hyperconcentration technology that complements its ENHANZE platform, potentially expanding addressable markets for biologics delivery and future royalty streams. Contract Pharma
• Positive Sentiment: Analyst support — H.C. Wainwright reiterated a Buy and keeps a $90 price target, citing strategic and financial strength of the ENHANZE platform, which may sustain analyst/retail demand. InsiderMonkey
• Neutral Sentiment: Longer‑term projections published — Management outlined sustained growth into the 2030s/2040s driven by ENHANZE and new technologies; important for long‑term investors but less decisive for near‑term moves. Benzinga
• Neutral Sentiment: Management call and filings available — Q4/2025 sales/trading call transcript and slides provide detail for modeling royalty cadence, margin assumptions and Surf Bio integration plans; useful for updating forecasts. Seeking Alpha
• Negative Sentiment: EPS guidance nuance — 2026 non‑GAAP EPS was set at $7.75–$8.25 versus consensus ~ $7.86; while revenue/royalty guidance was raised, the EPS range overlaps but is not meaningfully above consensus, which could temper upside for EPS‑sensitive investors. PR Newswire

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the sale, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Cortney Caudill sold 4,263 shares of the business’s stock in a transaction dated Saturday, November 1st. The shares were sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the transaction, the chief operating officer owned 12,737 shares in the company, valued at approximately $830,325.03. The trade was a 25.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 45,661 shares of company stock worth $3,139,257. 2.40% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. Zacks Research lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target for the company in a report on Tuesday, October 14th. Finally, TD Cowen raised their price objective on Halozyme Therapeutics from $79.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of “Hold” and a consensus target price of $78.80.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.